Diffusion-weighted MRI (DWI) for assessment of response to high-dose-rate CT-guided brachytherapy (HDR-BT) of hepatocellular carcinoma.
Diffusion-weighted imaging
hepatocellular carcinoma
image-guided interstitial brachytherapy
local ablative therapy
therapy response / prediction
Journal
Acta radiologica (Stockholm, Sweden : 1987)
ISSN: 1600-0455
Titre abrégé: Acta Radiol
Pays: England
ID NLM: 8706123
Informations de publication
Date de publication:
26 Feb 2023
26 Feb 2023
Historique:
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
28
2
2023
Statut:
aheadofprint
Résumé
High-dose-rate computed tomography (CT)-guided brachytherapy (HDR-BT) has shown promising results in patients with hepatocellular carcinoma (HCC). While growing evidence shows clear limitations of mRECIST, diffusion-weighted imaging (DWI) has relevant potential in improving the response assessment. To assess whether DWI allows evaluation of short- and long-term tumor response in patients with HCC after HDR-BT. A total of 22 patients with 11 non-responding HCCs (NR-HCC; local tumor recurrence within two years) and 24 responding HCCs (R-HCC; follow-up at least two years) were included in this retrospective bi-center study. HCCs were treated with HDR-BT and patients underwent pre- and post-interventional magnetic resonance imaging (MRI). Analyses of DWI were evaluated and compared between pre-interventional MRI, 1.follow-up after 3 months and 2.follow-up at the time of the local tumor recurrence (in NR-HCC) or after 12 months (in R-HCC). ADC The tumor response after CT-guided HDR-BT was associated with a significantly higher increase in ADC
Sections du résumé
BACKGROUND
BACKGROUND
High-dose-rate computed tomography (CT)-guided brachytherapy (HDR-BT) has shown promising results in patients with hepatocellular carcinoma (HCC). While growing evidence shows clear limitations of mRECIST, diffusion-weighted imaging (DWI) has relevant potential in improving the response assessment.
PURPOSE
OBJECTIVE
To assess whether DWI allows evaluation of short- and long-term tumor response in patients with HCC after HDR-BT.
MATERIAL AND METHODS
METHODS
A total of 22 patients with 11 non-responding HCCs (NR-HCC; local tumor recurrence within two years) and 24 responding HCCs (R-HCC; follow-up at least two years) were included in this retrospective bi-center study. HCCs were treated with HDR-BT and patients underwent pre- and post-interventional magnetic resonance imaging (MRI). Analyses of DWI were evaluated and compared between pre-interventional MRI, 1.follow-up after 3 months and 2.follow-up at the time of the local tumor recurrence (in NR-HCC) or after 12 months (in R-HCC).
RESULTS
RESULTS
ADC
CONCLUSION
CONCLUSIONS
The tumor response after CT-guided HDR-BT was associated with a significantly higher increase in ADC
Identifiants
pubmed: 36843430
doi: 10.1177/02841851231154498
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM